| Original language | English (US) |
|---|---|
| Pages (from-to) | 1274-1277 |
| Number of pages | 4 |
| Journal | Allergy: European Journal of Allergy and Clinical Immunology |
| Volume | 76 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2021 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, No. 4, 04.2021, p. 1274-1277.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria
AU - Al-Shaikhly, Taha
AU - MacDonald, James W.
AU - Bammler, Theo K.
AU - Altman, Matthew C.
AU - Ayars, Andrew G.
AU - Petroni, Daniel H.
AU - Tilles, Stephen A.
AU - Henderson, William R.
N1 - Funding Information: T.A.‐S. has a patent microRNAs as Predictors of Response to Anti‐IgE Therapies in Chronic Spontaneous Urticaria pending. J.W.M. reports grant from Novartis Pharmaceuticals Corporation, during the conduct of the study; in addition, J.W.M. has a patent microRNAs as Predictors of Response to Anti‐IgE Therapies in Chronic Spontaneous Urticaria pending. T.K.B. reports grant from Novartis Pharmaceuticals Corporation, during the conduct of the study; in addition, T.K.B. has a patent microRNAs as Predictors of Response to Anti‐IgE Therapies in Chronic Spontaneous Urticaria pending. M.C.A. reports personal fees from Regeneron, outside the submitted work. A.G.A. has nothing to disclose. D.H.P. reports grant from Novartis Pharmaceuticals Corporation, during the conduct of the study; grants from Genentech, DBV Technologies, Aimmune, Regeneron, and NIH/NIAID (Immune Tolerance Network), outside the submitted work. S.A.T. reports grant from Novartis Pharmaceuticals Corporation, during the conduct of the study; grants from Genentech, DBV Technologies, Aimmune, Regeneron, and NIH/NIAID (Immune Tolerance Network); and personal fees from Aimmune, outside the submitted work. W.R.H. reports grant from Novartis Pharmaceuticals Corporation, during the conduct of the study; in addition, W.R.H. has a patent microRNAs as Predictors of Response to Anti‐IgE Therapies in Chronic Spontaneous Urticaria pending. Funding Information: We thank Lynne Mullen for ingenuity pathway analysis technical support at Qiagen, Catherine Feight, Jo Joslin, and Karen Kearns for nursing and administrative support at Seattle Allergy and Asthma Research Institute, and Zahra Afsharinejad and Sengkeo Srinouanprachan for isolation of extracellular vesicle microRNAs at the Functional Genomics and Bioinformatics Core Laboratory, Interdisciplinary Center for Exposures, Diseases, Genomics & Environment, University of Washington.
PY - 2021/4
Y1 - 2021/4
UR - https://www.scopus.com/pages/publications/85098329856
UR - https://www.scopus.com/pages/publications/85098329856#tab=citedBy
U2 - 10.1111/all.14702
DO - 10.1111/all.14702
M3 - Letter
C2 - 33314187
AN - SCOPUS:85098329856
SN - 0105-4538
VL - 76
SP - 1274
EP - 1277
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 4
ER -